诺和诺德中国制药有限公司

What 诺和诺德中国制药有限公司 does

Novo Nordisk (China) Pharmaceuticals Co., Ltd. (诺和诺德中国制药有限公司) is a wholly-owned China subsidiary of the Danish biopharmaceutical company Novo Nordisk A/S (Copenhagen: NOVO B), itself founded in 1923 and today operating in 80 countries with approximately 77,000 employees. The China entity was established in 1994 and operates a localized manufacturing plant in Tianjin (est. 1997), an R&D center in Beijing's Zhongguancun Life Science Park, and a trading entity in Shanghai, supported by a national distribution network spanning hospitals, clinics, retail pharmacies, and digital channels. The company is the China commercial extension of Novo Nordisk's global leadership in serious chronic disease therapeutics, with primary focus on diabetes (including the world's most comprehensive insulin portfolio and pioneering GLP-1 receptor agonists), plus adjacent franchises in obesity, hemophilia and rare blood disorders, growth hormone therapy, and endocrine disorders.

The company's product portfolio spans human insulin, first-generation insulin analogs, GLP-1 receptor agonists (both injectable and the world's first oral formulation, launched in 2019), the NovoPen insulin pen injector, insulin pumps, and continuous glucose monitoring (CGM) systems, complemented by obesity therapeutics, hemophilia treatments (Factor VIII / Factor IX replacement therapies), and human growth hormone replacement therapy. Underlying technology rests on a recombinant DNA and biopharmaceutical platform first commercialized in 1982 with the first recombinant human insulin, advanced through sustained investment in peptide chemistry, sustained-release formulations, and novel modalities such as glucose-responsive insulin and stem cell-derived beta-cell therapy (in research). The R&D pipeline emphasizes oral peptide delivery, obesity-targeted GLP-1 synthesis, hematology long-acting and subcutaneous therapies, and gene therapy research.

The business model is anchored on prescription drug sales through hospital and clinic channels plus retail pharmacy distribution for cold-chain products such as insulin, with hardware (devices) and digital services (the "诺和关怀" WeChat service offering pharmacy locator and patient registration) reinforcing the drug franchise. Revenue is therefore generated via prescription volume and device unit sales rather than transactional or subscription pricing. Pricing is not publicly disclosed; patients access products through physician prescriptions or purchase via retail pharmacies identified through the customer hotline (400-810-2299 / 800-810-2299) or digital locator. The company supplements core commercial activity with corporate social initiatives — including the World Diabetes Foundation, UNICEF childhood obesity program, ICRC/Danish Red Cross humanitarian partnership, and Cities Changing Diabetes — that strengthen institutional access and shape the regulatory and reimbursement environment for its products.

Name

诺和诺德中国制药有限公司

Legal name

诺和诺德（中国）制药有限公司

Website

https://novonordisk.com.cn

Company type

Public

Founded year

1923

Operating status

Operating

Headcount range

251–500 employees

Short description

Novo Nordisk (China) Pharmaceuticals is the wholly-owned China subsidiary of Danish biopharmaceutical leader Novo Nordisk A/S, commercializing insulin, GLP-1 receptor agonists, obesity, hemophilia, and growth hormone therapies through hospitals, retail pharmacies, and the "诺和关怀" digital service platform.

Ownership category

akta.pro rank

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. 处方药销售: 诺和诺德通过向医院、诊所和零售药店销售糖尿病治疗药物（包括各类胰岛素、GLP-1受体激动剂）、肥胖症治疗药物、罕见血液疾病治疗药物（血友病药物）和生长激素疗法产品获取收入。处方药需经医生处方在医院或药店购买。
2. 医疗器械与给药装置: 公司同时销售胰岛素笔、血糖监测设备等医疗器械和给药装置，与药物产品形成协同销售。

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

诺和诺德中国是全球领先的生物制药公司诺和诺德集团在华全资子公司，从事糖尿病、肥胖症、血友病、生长障碍及其他严重慢性疾病领域的处方药物研发、生产与销售。其核心产品包括人胰岛素、胰岛素类似物、GLP-1受体激动剂（注射和口服剂型）、血友病治疗药物、生长激素替代疗法以及配套的胰岛素给药装置（诺和笔®、胰岛素泵）和连续血糖监测系统。公司通过天津生产基地实现胰岛素等产品的本地化生产。

Product overview

诺和诺德中国是一家全球领先的生物制药公司，提供以糖尿病治疗为核心的多元化产品组合。公司拥有超过100年的历史，是医药行业中产品组合最丰富的企业之一。核心产品包括：各类胰岛素制剂（人胰岛素、胰岛素类似物）、GLP-1受体激动剂（注射和口服制剂）、胰岛素给药装置（诺和笔®胰岛素笔、胰岛素泵）、连续血糖监测系统，以及治疗肥胖症、生长障碍和血友病的创新药物。公司还通过诺和关怀数字服务平台（微信服务号和小程序）为患者提供药店地图查询、药品注册等增值服务，形成涵盖药物、器械和数字化服务的综合慢病管理生态。

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 全球每11人中有1人患有糖尿病，诺和诺德的药物覆盖全球超过170个国家和地区的大量患者
• +4 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Seven partnerships are on record, tiered core and flagship.

• International Committee of the Red Cross and Danish Red Cross（国际红十字委员会和丹麦红十字会）coreStrategic or Co-development Partner · 1 January 2023诺和诺德与国际红十字委员会和丹麦红十字会合作开展'携手改变'（Partnering for change）项目，为身处人道主义危机的最弱势患者群体提供帮助。项目合作年限延长至2023年，诺和诺德捐赠1500万丹麦克朗支持该项目。
• UNICEF（联合国儿童基金会）coreStrategic or Co-development Partner · 1 January 2019诺和诺德与联合国儿童基金会合作预防儿童超重和肥胖症，项目初期主要在墨西哥和哥伦比亚进行干预，后逐渐在全球其他区域产生更广泛影响力。目标是将预防超重和肥胖症的观念从关注个人责任转向解决引起肥胖症的环境问题。
• Novo Nordisk Haemophilia Foundation（诺和诺德血友病基金会）coreStrategic or Co-development Partner · 1 January 2019诺和诺德血友病基金会是一家资助型非盈利组织，致力于提升治疗可及性，以造福发展中国家和新兴国家血友病及相关出血性疾病患者。3/4的血友病患者生活在发展中国家，迫切需要保证他们能够得到治疗和合理的医疗保障。
• University College London and Copenhagen Steno Diabetes Center（伦敦大学学院和哥本哈根Steno糖尿病中心）coreStrategic or Co-development Partner · 1 January 2014诺和诺德与伦敦大学学院和哥本哈根Steno糖尿病中心共同创立了'城市糖尿病'概念，发起'城市改变糖尿病'全球合作项目。已在全球超过40个城市开展，超过150个合作伙伴加入，共同推进2型糖尿病研究和政策支持。
• 全球领先院校和生物技术公司coreStrategic or Co-development Partner · 1 January 2014诺和诺德与全球领先的院校和生物技术公司密切合作，共同加快新药研发。公司将引以为傲的研发资源以便捷的方式免费提供给世界各地的科学家，并将持续探索创新疗法如干细胞疗法和基因疗法。
• World Diabetes Foundation（世界糖尿病基金会）flagshipStrategic or Co-development Partner · 1 January 2002世界糖尿病基金会由诺和诺德于2002年成立，是一家独立的非盈利基金会，致力于为发展中国家糖尿病预防和治疗活动提供支持。诺和诺德承诺到2024年前累计向基金会捐赠16.9亿丹麦克朗（2.77亿美元）。基金会支持可持续合作，积极充当推动者角色。
• 全球各国卫生部门coreStrategic or Co-development Partner在已有业务运营的国家，诺和诺德致力于与各国卫生部门开展合作，共同预防并治疗糖尿病，推动药物可及性和可负担性项目。超过2/3的业务所在国开展了相关项目。

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/%E8%AF%BA%E5%92%8C%E8%AF%BA%E5%BE%B7%E4%B8%AD%E5%9B%BD%E5%88%B6%E8%8D%AF%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 诺和诺德中国制药有限公司